Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 4/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.33 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 9/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.31 |
| ▸ | MPO | P05164 | 2/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23833328 | 0.86 | — | — | |
| SCHEMBL23833129 | 0.86 | ADRB2 (0.33) | SLC1A5ADRB2ADRB1 | |
| SCHEMBL26206494 | 0.82 | ADRB2 (0.37) | LTB4RLTB4R2ADRB2ADRB1MPO | |
| SCHEMBL23833042 | 0.79 | — | — | |
| SCHEMBL30169029 | 0.78 | AAK1 (0.40) | ADRB2ADRB1 | |
| SCHEMBL22525576 | 0.78 | AAK1 (0.40) | ADRB2ADRB1 | |
| SCHEMBL23833164 | 0.78 | AAK1 (0.40) | ADRB2ADRB1 | |
| SCHEMBL23833230 | 0.75 | MRGPRX4 (0.39) | SLC1A5ADRB2 | |
| SCHEMBL22527061 | 0.75 | MPO (0.40) | LTB4RLTB4R2SLC1A5ADRB2ADRB1 | |
| SCHEMBL26206421 | 0.75 | LTB4R (0.44) | LTB4RLTB4R2ADRB2ADRB1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4121055-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188696-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | LTB4R 2439/4885LTB4R2 2981/4885SLC1A5 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.